StreetInsider.com News Articles

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET.

A live webcast of Ironwood’s fireside chat will be accessible through the Investors & Media section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The U.S. Food and Drug Administration has approved the expanded use of LINZESS (linaclotide) for pediatric patients 2 years of age and older with functional constipation, according to Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). The drug was previously approved for pediatric patients 6 years and older with the condition.

LINZESS remains the only FDA-approved prescription therapy for pediatric functional constipation. Functional constipation in children is characterized by hard, infrequent bowel movements that are often difficult or painful to pass, with an estimated worldwide prevalence of 3% among preschool children.

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA approves LINZESS for children ages 2-5 with functional constipation

Wed, 27 May 2026 10:00:26 -0400

The approval for patients ages 2-5 was supported by data from a 12-week Phase

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)